Regenerative Medicine & Longevity Sciences

Advancing the
Science of Human
Restoration

Suncoast Health Group is a regenerative medicine and longevity sciences group whose proprietary protocol portfolio underpins a growing network of affiliated clinics, practitioners, and health sector partners across the United States, the Bahamas, and the Cayman Islands.

Explore Our Portfolio Our Structure
4
Therapeutic Pillars
34+
Protocol Modalities
3
Territories
Who We Are

The Group Behind
the Science

Suncoast Health Group is a regenerative medicine and longevity sciences holding group built on a portfolio of proprietary therapeutic patents. The group operates as the intellectual and structural backbone behind a curated network of affiliated clinics, practitioners, and health sector entities — providing the protocol frameworks, scientific standards, and licensing infrastructure through which advanced therapies are delivered.

The group does not operate as a direct clinical provider. Rather, it develops, owns, and licenses the therapeutic protocols that its affiliated clinical partners deploy — ensuring consistency, scientific integrity, and outcome accountability across every entity operating under the Suncoast Health Group framework.

Patent-Backed Protocols
Proprietary intellectual property developed through sustained research and clinical refinement underpins every protocol within the group's portfolio.
Affiliated Clinical Network
A carefully curated network of credentialed clinical partners deploys the group's protocols under rigorous quality and compliance standards.
Scientific Governance
A dedicated medical and scientific advisory function oversees protocol integrity, evidence review, and the continuous integration of emerging research.
Multi-Sector Reach
The group's portfolio spans regenerative medicine, sexual health, longevity science, injury recovery, and peptide therapeutics — unified under a single scientific framework.
A Multi-Jurisdictional Structure
Operating across the United States, the Bahamas, and the Cayman Islands provides the Suncoast Health Group network with a distinctive regulatory and geographic advantage. Affiliated clinical entities benefit from access to the full spectrum of available therapeutic modalities — many subject to differing approval stages across jurisdictions — while operating under the oversight of licensed medical professionals within each territory's applicable governance structure.
Network Coverage
United States — Licensed practitioners across multiple states
The Bahamas — Nassau & Paradise Island
The Cayman Islands — Grand Cayman
Therapeutic Portfolio

Four Disciplines.
One Scientific Framework.

01
Regenerative Medicine

Protocols leveraging the body's own biological machinery — stem cells, growth factors, exosomes, and plasma concentrates — to repair damaged tissue, reduce chronic inflammation, and restore cellular function. This pillar represents the scientific core of the group's IP portfolio and the foundation from which affiliated clinical entities deliver advanced biological repair.

8 Protocol Modalities
02
Sexual Health

A science-forward protocol suite addressing the biological, hormonal, and neurovascular dimensions of sexual function and vitality. The group's sexual health portfolio moves beyond symptomatic management to target the underlying physiological conditions that govern healthy sexual function across age groups.

7 Protocol Modalities
03
Health Longevity

A comprehensive longevity science framework targeting the established hallmarks of biological aging — cellular senescence, mitochondrial decline, hormonal depletion, immune dysregulation, and progressive loss of regenerative capacity. The group's longevity portfolio is among the most comprehensive available in the private clinical sector.

10 Protocol Modalities
04
Injury Recovery

Precision biological intervention protocols for acute and chronic musculoskeletal pathology — replacing the limitations of conventional management with targeted regenerative therapies that directly stimulate biological healing of tendons, ligaments, cartilage, neural structures, and joints.

9 Protocol Modalities
Protocol Portfolio

Therapeutic Modalities

The following represents the current licensed protocol portfolio of Suncoast Health Group. Each modality is developed and maintained against a framework of peer-reviewed evidence, proprietary clinical data, and the group's established scientific governance standards. Deployment occurs exclusively through credentialed affiliated clinical partners.

Stem Cell Therapy
+
The group's stem cell protocols deploy concentrated mesenchymal stem cells to repair damaged tissue, reduce chronic inflammation, and restore function at the cellular level. Protocol variants utilise both autologous and allogeneic sources — including umbilical cord-derived Wharton's Jelly MSCs — calibrated to the specific therapeutic indication. Clinical application spans orthopedic, autoimmune, neurological, and systemic inflammatory pathologies.
Exosome Therapy
+
Exosomes are nano-sized extracellular vesicles secreted by stem cells that function as molecular messengers directing tissue repair and cellular regeneration. The group's exosome protocols deliver concentrated signaling molecules to target tissues, amplifying the regenerative response without the complexity of full cell transplantation. Exosomes carry growth factors, micro-RNA, and cytokines that instruct local cellular populations to reduce inflammation, proliferate, and restore function.
Platelet-Rich Plasma (PRP)
+
PRP protocols concentrate growth factors and healing proteins from autologous blood to deliver a targeted regenerative signal to injured or degenerating tissue. Deployed across orthopedic, aesthetic, and sexual health applications, PRP stimulates collagen production, accelerates tissue repair, and promotes vascular regeneration. Processing achieves platelet-rich concentrations typically five to ten times above baseline, providing a potent biological stimulus at the precise site of pathology.
Platelet-Rich Fibrin (PRF)
+
An advanced evolution of standard PRP methodology, PRF produces a natural fibrin scaffold enriched with platelets, growth factors, and leukocytes. PRF releases its regenerative factors progressively over time, providing sustained biological support superior to standard PRP in applications requiring extended healing stimulus. The fibrin matrix also functions as a scaffold for new tissue ingrowth, conferring particular value in wound healing, joint restoration, and procedures requiring both structural support and biological regeneration.
Bone Marrow Aspirate Concentrate (BMAC)
+
BMAC harvests the body's most potent autologous regenerative cells — mesenchymal stem cells, hematopoietic progenitors, and a rich growth factor milieu — directly from the iliac crest. The concentrate is processed chairside for same-session injection, preserving maximum cell viability. BMAC delivers exceptional regenerative potential for orthopedic pathology, chronic joint conditions, and cartilage repair, representing the most concentrated form of autologous biological therapy in the group's portfolio.
Wharton's Jelly MSC Therapy
+
Derived from umbilical cord matrix, Wharton's Jelly mesenchymal stem cells represent one of the most potent and immune-tolerant allogeneic stem cell sources available. These highly proliferative cells carry exceptional regenerative capacity and are deployed in the group's most advanced protocols for systemic inflammation, autoimmune conditions, and complex tissue repair. Their immune-privileged status permits allogeneic administration without immunosuppression, significantly broadening the clinical population for whom this modality is appropriate.
Growth Factor Therapy
+
Targeted delivery of specific growth factors — including VEGF, EGF, FGF, and IGF-1 — directs tissue remodeling, angiogenesis, and cellular proliferation at the treatment site with molecular precision. Growth factor protocols are frequently combined with other regenerative modalities to amplify and focus the healing response. Protocol design is based on the specific biological signaling requirements of each clinical indication.
Prolotherapy
+
Prolotherapy employs precisely formulated irritant solutions injected into damaged ligaments, tendons, and joint structures to stimulate the body's endogenous healing cascade. The controlled inflammatory response promotes collagen synthesis and connective tissue repair. Clinical application is particularly established in chronic ligamentous laxity, spinal instability, and joint dysfunction that has not responded to conventional conservative management.
P-Shot (Priapus Shot)
+
The P-Shot protocol delivers concentrated PRP to penile tissue to stimulate new blood vessel formation, improve nerve sensitivity, and address erectile dysfunction through biological regeneration. The protocol has a strong published safety record and is deployed by affiliated practitioners as a non-surgical intervention for vasculogenic erectile dysfunction and sexual performance optimization. Clinical outcomes develop progressively as growth factors stimulate vascular and tissue regeneration within the treated anatomy.
O-Shot (Orgasm Shot)
+
The O-Shot protocol delivers PRP to clitoral and anterior vaginal wall tissue to regenerate sensitive anatomy, enhance arousal response, and address diminished sexual function. Published clinical data supports meaningful improvements in arousal, sensitivity, and orgasmic function following treatment. The protocol also demonstrates clinical utility in mild-to-moderate stress urinary incontinence, offering dual therapeutic value within a single procedural framework.
GAINSWave / Low-Intensity Shockwave Therapy
+
Low-intensity extracorporeal shockwave therapy delivers acoustic energy to penile vascular tissue, disrupting micro-plaque deposits, stimulating neovascularization, and activating dormant stem cells within the vascular architecture. This non-invasive protocol has demonstrated strong clinical outcomes for vasculogenic erectile dysfunction across multiple controlled studies and represents a drug-free, surgery-free modality with no associated downtime.
Vaginal Rejuvenation
+
The group's vaginal rejuvenation protocols combine energy-based modalities, growth factor interventions, and targeted peptide and hormone therapies to address laxity, atrophic vaginitis, stress urinary incontinence, and dyspareunia arising from hormonal transition, childbirth, or aging. Protocol selection is anatomy- and indication-specific, drawing from the group's PRP, PRF, hormonal optimization, and peptide modalities to construct a comprehensive treatment framework.
PT-141 / Bremelanotide
+
PT-141 is a melanocortin receptor agonist peptide that acts centrally on the nervous system to enhance sexual desire across both sexes. Unlike PDE5 inhibitor approaches, PT-141 engages a neural rather than vascular mechanism — particularly relevant where diminished libido is the primary presenting complaint. The compound is the active ingredient in FDA-approved Vyleesi for hypoactive sexual desire disorder, and features in the group's male sexual health protocols as part of a comprehensive multi-mechanism approach.
Hormone Optimization
+
Comprehensive hormonal assessment and optimization — encompassing testosterone, estrogen, progesterone, DHEA, and full thyroid evaluation — forms the endocrine foundation of sexual health and systemic vitality within the group's protocol framework. Bioidentical hormone protocols are calibrated against comprehensive laboratory panels, clinical presentation, and defined therapeutic goals. Ongoing monitoring and titration ensures optimal hormonal status is maintained safely over time.
Peptide Therapy for Sexual Vitality
+
Beyond PT-141, the group's sexual health portfolio incorporates a targeted panel of peptides — including Kisspeptin, Selank, and Epithalon — supporting the neuroendocrine pathways governing desire, arousal, and reproductive hormone production. These protocols are structured to complement the group's hormonal optimization and structural intervention modalities, creating a layered biological approach to sexual vitality that addresses the relevant pathophysiology across multiple axes simultaneously.
NAD+ IV Therapy
+
Nicotinamide adenine dinucleotide (NAD+) is a critical coenzyme governing cellular energy production, DNA repair, and sirtuin activation — the longevity-associated proteins regulating cellular stress response. NAD+ levels decline significantly with biological age, contributing to progressive metabolic and cognitive deterioration. High-dose intravenous replenishment restores this coenzyme at the cellular level, supporting mitochondrial function, metabolic efficiency, cognitive clarity, and the endogenous capacity for cellular self-repair.
Sermorelin / Ipamorelin / CJC-1295
+
These growth hormone secretagogue peptides stimulate endogenous pituitary GH production, restoring a physiologically appropriate pulsatile GH release pattern without the risks associated with exogenous HGH. Used in combination, the protocol drives clinically meaningful improvements in lean body composition, adipose metabolism, sleep architecture, skin integrity, immune function, and recovery capacity — a cornerstone of the group's biological age management framework.
Thymosin Alpha-1
+
Thymosin Alpha-1 is a naturally occurring thymic peptide with well-documented immunomodulatory properties, enhancing T-cell function, natural killer cell activity, and innate immune surveillance — capabilities that diminish as thymic involution progresses with age. The compound has established clinical utility in chronic viral infections, post-illness immune reconstitution, and longevity protocols oriented around long-term immune resilience and cancer immunosurveillance.
Telomere Support Protocols
+
Telomere length is among the most extensively studied biomarkers of biological aging. The group's protocols integrate evidence-backed nutraceuticals, peptides including Epithalon — which has demonstrated telomerase activation in preclinical models — targeted hormonal optimization, and structured lifestyle interventions to modulate telomere attrition. Baseline and serial telomere testing provides objective longitudinal data on the biological response to intervention.
Hyperbaric Oxygen Therapy (HBOT)
+
HBOT delivers 100% oxygen under elevated atmospheric pressure, achieving tissue oxygen saturation levels unattainable under ambient conditions. Resulting physiological cascades include neuroplasticity induction, angiogenesis, mitochondrial biogenesis, and sustained anti-inflammatory signaling. Published research has demonstrated HBOT's capacity to lengthen telomeres and reduce senescent cell burden in aging adults — positioning it as a validated anti-aging modality alongside established applications in wound healing and post-ischemic recovery.
Photobiomodulation / Red Light Therapy
+
Low-level laser and red/near-infrared light therapy acts on cytochrome c oxidase in the mitochondrial electron transport chain, augmenting cellular ATP production and attenuating systemic oxidative stress. The clinical evidence base spans more than 5,000 peer-reviewed publications, with established applications in skin biology, cognitive function, musculoskeletal recovery, joint health, and systemic anti-aging. The modality is integrated throughout the group's longevity, recovery, and regenerative protocol suites.
Personalized Genomics & Nutrigenomics
+
Advanced genomic profiling identifies individual SNPs governing metabolic function, inflammatory pathway activity, detoxification capacity, and micronutrient utilization. These data inform hyper-individualized supplementation, dietary, and therapeutic protocols calibrated to each individual's genetic architecture — moving the group's longevity framework from population-based guidelines to genuinely precision medicine.
Senolytic Protocols
+
Senescent cells accumulate progressively with age and drive chronic tissue inflammation through the senescence-associated secretory phenotype (SASP). The group's senolytic protocols incorporate targeted pharmaceutical agents including dasatinib/quercetin combinations alongside adjunct peptide interventions, selectively clearing the senescent cell burden and attenuating SASP-mediated inflammatory signaling. This represents one of the most active translational frontiers in aging science.
Metformin / Rapamycin Longevity Protocols
+
Physician-supervised pharmaceutical longevity interventions — including metformin (AMPK pathway activation, subject of the ongoing TAME trial) and low-dose rapamycin (mTOR1 inhibition, the most replicated lifespan-extending intervention in model organism research) — are integrated into the group's comprehensive biological aging programs. All pharmaceutical longevity protocols are administered under strict medical supervision with structured laboratory and clinical monitoring.
IV Nutrient & Micronutrient Optimization
+
Intravenous delivery achieves plasma concentrations of vitamins, minerals, antioxidants, and amino acids that oral supplementation cannot replicate due to gastrointestinal absorption constraints. Protocols — encompassing high-dose Vitamin C, glutathione, B-complex, magnesium, zinc, and individualized amino acid formulations — are built from comprehensive laboratory assessment of baseline status and clinical objectives, functioning as both standalone interventions and synergistic adjuncts within broader longevity and recovery frameworks.
BPC-157 & TB-500 Peptides
+
Body Protection Compound-157 and Thymosin Beta-4 are among the most extensively studied peptides for musculoskeletal tissue healing. BPC-157 accelerates tendon, ligament, and muscle repair through upregulation of growth hormone receptors and promotion of targeted angiogenesis. TB-500 promotes actin polymerization, directed cell migration, and anti-inflammatory signaling at injury sites. In combination, these compounds form a synergistic recovery protocol applicable to acute injuries, chronic tendinopathies, and post-surgical rehabilitation.
GHK-Cu (Copper Peptide)
+
GHK-Cu is a naturally occurring copper-binding tripeptide with well-characterised tissue remodeling and anti-inflammatory properties. It stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis at healing sites, and modulates pro-inflammatory gene expression through NF-kB pathway interaction. Both systemic and topical deployment within the group's protocols make GHK-Cu a versatile component of connective tissue repair, scar remodeling, and post-injury tissue architecture restoration.
PRP Injections for Musculoskeletal Repair
+
Ultrasound-guided PRP injection delivers concentrated autologous growth factors with anatomical precision to injured tendons, ligaments, cartilage, and joint structures. This approach stimulates endogenous repair mechanisms directly at the site of pathology, accelerating biological healing and reducing the necessity for surgical intervention in many clinical scenarios. Well-established evidence exists for partial rotator cuff tears, patellar tendinopathy, lateral epicondylitis, Achilles tendinopathy, and early-to-moderate osteoarthritic joint presentations.
Platelet-Rich Fibrin (PRF) for Tissue Repair
+
PRF's fibrin scaffold provides sustained-release delivery of growth factors at the repair site, offering superior tissue adhesion and prolonged regenerative signaling relative to standard PRP. The fibrin matrix functions as a biological scaffold supporting new tissue ingrowth while maintaining a local growth factor reservoir over a multi-day to multi-week period — particularly effective in joint and soft tissue repairs requiring extended biological support throughout the healing window.
Extracorporeal Shockwave Therapy (ESWT)
+
Focused or radial acoustic shockwave delivery to chronic tendinopathies, calcific deposits, and recalcitrant soft tissue injuries stimulates neovascularization, disrupts pathological calcification, and activates resident stem cell populations within the treatment zone. ESWT has a well-developed evidence base for plantar fasciitis, Achilles tendinopathy, calcific rotator cuff tendinitis, and patellar tendinopathy. The non-invasive nature and absence of recovery downtime support its integration into active clinical protocols.
Ozone Therapy (Joint Injections)
+
Intra-articular ozone injection delivers a calibrated ozone-oxygen mixture into affected joint spaces, producing anti-inflammatory, analgesic, and cartilage-protective effects through modulation of oxidative signaling pathways. The protocol reduces local inflammatory mediator concentrations and stimulates endogenous antioxidant systems, positioned within the group's recovery portfolio as a valuable adjunct in osteoarthritis management, chronic synovitis, and joint pain presentations.
Neural Prolotherapy
+
Neural prolotherapy employs subcutaneous low-concentration dextrose injections adjacent to superficial sensory nerves to reduce neurogenic inflammation and central sensitization. The protocol demonstrates particular clinical utility in post-traumatic pain syndromes, peripheral nerve entrapment conditions, and complex regional pain states where structural interventions alone have proved insufficient. It addresses the neural component of chronic musculoskeletal pain that tissue-based treatments alone cannot resolve.
Stem Cell Injections for Joint Restoration
+
Intra-articular mesenchymal stem cell injection — whether from autologous bone marrow or adipose sources, or allogeneic Wharton's Jelly — provides a potent regenerative stimulus for cartilage repair, synovial inflammation reduction, and restoration of joint homeostasis. A growing body of controlled clinical evidence supports application in moderate-to-severe osteoarthritis and post-surgical joint deterioration, with outcomes data indicating meaningful improvements in function and symptom burden.
Sports Medicine Rehabilitation Integration
+
The group's recovery protocols are designed for structured integration with supervised physical rehabilitation programs. Coordinated care between the group's biological intervention framework and sports medicine rehabilitation ensures that tissue repair stimulated by regenerative protocols is matched by progressive functional loading — the mechanical input required to remodel regenerating tissue into fully functional anatomy. This integrated model is standard within all affiliated clinical partnerships.
Regulatory Notice

The peptide compounds documented within this portfolio are not approved drugs by the United States Food and Drug Administration or the equivalent regulatory authorities of other jurisdictions in which Suncoast Health Group's affiliated clinical partners operate. Many compounds listed are available through licensed compounding pharmacies in the United States under valid physician prescription, consistent with evolving FDA guidance effective April 2026, following reclassification of a significant number of peptide compounds from FDA Category 2 restricted status back to Category 1 compounding eligibility. Legal status, prescribing frameworks, and availability vary by jurisdiction. All compounds within the Suncoast Health Group protocol portfolio are administered exclusively under the supervision of licensed medical professionals operating within applicable regulatory frameworks. The information presented here is intended for educational and portfolio documentation purposes only and does not constitute medical advice, a treatment recommendation, or a solicitation of any kind.

Recovery & Tissue Repair
BPC-157 (Body Protection Compound)
+
A gastric pentadecapeptide with extensively documented tendon, ligament, and muscle healing properties. Mechanism of action involves upregulation of growth hormone receptor expression at injury sites, promotion of targeted angiogenesis, and modulation of nitric oxide signaling. BPC-157 is among the most widely studied peptides in the musculoskeletal healing context. Reclassified from FDA Category 2 to Category 1 compounding eligibility effective April 2026.
TB-500 (Thymosin Beta-4)
+
A naturally occurring 43-amino acid peptide promoting actin polymerization, directed cell migration to injury sites, anti-inflammatory signaling, and systemic tissue repair. Its mechanism complements BPC-157 and the compounds function synergistically when co-administered. TB-500 has demonstrated preclinical efficacy in cardiac, neural, and musculoskeletal tissue repair contexts. Reclassified from FDA Category 2 to Category 1 compounding eligibility effective April 2026.
GHK-Cu (Copper Peptide)
+
A naturally occurring copper-binding tripeptide with well-characterised tissue remodeling, angiogenic, and anti-inflammatory properties. GHK-Cu stimulates collagen and glycosaminoglycan synthesis, reduces NF-kB-mediated inflammatory gene expression, and demonstrates broad applicability in wound healing, scar remodeling, skin biology, and connective tissue restoration. Available via licensed compounding and deployed across the group's recovery, regenerative, and longevity protocol suites.
LL-37
+
The sole member of the human cathelicidin family of host defence peptides, with demonstrated antimicrobial, anti-biofilm, and immunomodulatory properties alongside emerging applications in wound healing and tissue repair. LL-37 promotes keratinocyte migration, angiogenesis, and epithelial regeneration at wound sites. It is integrated within the group's more complex wound and tissue repair protocols.
Longevity & Cellular Health
Epithalon (Epitalon)
+
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the naturally occurring pineal peptide epithalamin. Studied extensively for its capacity to activate telomerase, extend telomere length in somatic cells, regulate pineal melatonin secretion, and restore circadian and neuroendocrine function in aging models. Integrated within the group's telomere support and longevity protocols as one of the few compounds with direct evidence of telomerase-modulating activity in research settings.
MOTS-c
+
A mitochondrially encoded peptide functioning as a metabolic regulator, improving insulin sensitivity, activating AMPK signaling, and enhancing cellular stress response. Circulating MOTS-c levels have been identified as a potential biomarker of biological aging. Emerging research supports its role in metabolic health, physical performance, and longevity pathway modulation.
Humanin
+
A mitochondrially encoded cytoprotective peptide with neuroprotective, cardioprotective, and metabolic regulatory properties. Circulating Humanin levels decline with age and associate with disease risk and longevity outcomes in epidemiological studies. Preclinical and early clinical research supports its role in reducing cellular apoptosis, improving insulin signaling, and protecting against neurodegenerative pathology.
5-Amino-1MQ
+
A small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that reduces NAD+ precursor availability in metabolic tissues. By inhibiting NNMT, 5-Amino-1MQ supports NAD+ pathway optimization, promotes metabolic efficiency, reduces lipid accumulation, and has demonstrated promising results for body composition and metabolic health in preclinical models. Deployed within the group's metabolic longevity protocols as a complement to NAD+ replenishment strategies.
Growth Hormone Axis
Sermorelin
+
A synthetic analogue of the first 29 amino acids of endogenous GHRH, stimulating the pituitary gland's natural GH secretion through a physiologically appropriate mechanism. Preserves the pulsatile release pattern of endogenous GH, avoiding risks associated with direct exogenous HGH. Clinical applications include lean composition support, adipose metabolism, sleep quality, skin integrity, and systemic recovery — core components of the group's biological age management protocols.
Ipamorelin
+
A selective GH secretagogue and ghrelin receptor agonist notable for its clean pulsatile GH stimulation profile and minimal impact on cortisol or prolactin levels. This selectivity makes it the preferred GHRP within the group's GH axis protocols, typically combined with CJC-1295 for synergistic effect across longevity and recovery clinical contexts.
CJC-1295
+
A long-acting GHRH analogue that sustains elevated baseline GH and IGF-1 levels through an extended half-life achieved via drug affinity complex technology. Combined with Ipamorelin, it creates a two-mechanism approach to GH axis restoration addressing both GHRH and ghrelin receptor pathways simultaneously — a cornerstone combination within the group's longevity and body composition frameworks.
GHRP-2 / GHRP-6
+
First-generation growth hormone releasing peptides acting on the ghrelin receptor to stimulate robust GH secretion. GHRP-2 is associated with a stronger GH pulse, while GHRP-6 produces a notable appetite-stimulating effect lending clinical utility in cachexia, wasting conditions, and post-operative recovery contexts where anabolic support and nutritional intake are therapeutic priorities.
Hexarelin
+
A potent synthetic hexapeptide GH secretagogue with additional cardioprotective properties mediated through direct interaction with CD36 receptors in cardiac and vascular tissue. Preclinical research has demonstrated capacity to protect cardiomyocytes from ischemic injury and support cardiac function. This dual-mechanism profile makes Hexarelin a unique component within the group's longevity and cardiovascular health protocol frameworks.
Tesamorelin
+
A stabilized GHRH analogue with FDA approval (as Egrifta) for HIV-associated lipodystrophy — one of the few peptides in the group's portfolio with a formal approved indication. Beyond its approved use, Tesamorelin is studied for visceral adiposity reduction, IGF-1 optimization, and metabolic health improvement across broader populations. Its regulatory status and established clinical evidence base give it a distinct profile within the group's metabolic longevity and body composition protocol suite.
Cognitive & Neurological
Semax
+
A synthetic heptapeptide analogue of the ACTH 4-10 fragment with approved clinical status in Russia for stroke and cognitive impairment. Primary mechanisms include upregulation of BDNF, VEGF, and serotonergic/dopaminergic neurotransmission, producing neuroprotective, cognitive-enhancing, and mood-stabilizing effects. Semax has one of the most robust basic science evidence bases of any peptide in the cognitive longevity category. Reclassified from FDA Category 2 to Category 1 effective April 2026.
Selank
+
A synthetic analogue of the endogenous immunomodulatory tetrapeptide tuftsin, with documented anxiolytic, nootropic, and immunomodulatory properties. Modulates serotonin transporter gene expression and has demonstrated efficacy in generalized anxiety disorder in clinical trials. Beyond its anxiolytic profile, Selank supports cognitive function, working memory, and stress resilience. Reclassified from FDA Category 2 to Category 1 effective April 2026.
Dihexa
+
A hepatocyte growth factor modulator developed at Washington State University demonstrating potent synaptogenic activity — the capacity to stimulate formation of new functional synaptic connections. In preclinical models, Dihexa has shown efficacy orders of magnitude greater than BDNF in reversing cognitive deficits associated with neurodegeneration. Incorporated within the group's advanced neuroprotection and cognitive longevity protocols.
NA-Semax Amidate
+
A modified and more bioavailable variant of Semax, featuring an N-acetyl group and C-terminal amidation that enhance metabolic stability and CNS penetration. These structural modifications produce a more sustained BDNF-upregulating effect and an amplified cognitive and neuroprotective profile relative to standard Semax — the preferred variant within the group's cognitive longevity protocols where sustained neurotrophin support and maximum CNS bioavailability are treatment priorities.
Metabolic & Body Composition
AOD-9604
+
A modified fragment of the C-terminus of human growth hormone (hGH 177-191) retaining fat metabolism-regulating properties without the growth-promoting or insulin-desensitizing effects of full-length HGH. Acts on beta-3 adrenergic receptors to stimulate lipolysis and inhibit lipogenesis, with particular efficacy in visceral and abdominal adipose depots. Its favourable safety profile makes it a preferred component of the group's metabolic health and body composition protocol suite.
KPV
+
A C-terminal tripeptide fragment of alpha-MSH (Lys-Pro-Val) with potent and selective anti-inflammatory properties mediated through direct melanocortin receptor interaction and NF-kB nuclear translocation inhibition. Anti-inflammatory activity has been studied extensively in gastrointestinal inflammatory pathology, with broader systemic applications including skin inflammation, wound healing acceleration, and metabolic inflammation modulation emerging from ongoing research.
GLP-1 Receptor Agonist Protocols
+
The GLP-1 receptor agonist class — including semaglutide analogues and related incretin-based compounds — represents the most clinically active peptide category in contemporary metabolic medicine. Beyond established metabolic and weight management indications, emerging research documents significant cardiovascular risk reduction, neuroprotective, and potentially longevity-relevant effects through GLP-1 pathway modulation. The group's metabolic protocols incorporate GLP-1 class interventions within a broader metabolic health and longevity framework, administered under physician supervision with appropriate monitoring.
Sexual Health & Vitality
PT-141 / Bremelanotide
+
A cyclic heptapeptide melanocortin receptor agonist acting centrally on MC3R and MC4R receptors within the hypothalamus to enhance sexual desire and arousal through a neural rather than vascular mechanism. This central mode of action distinguishes it from PDE5 inhibitors and makes it relevant across contexts where diminished libido is the primary complaint. PT-141 is the active ingredient in FDA-approved Vyleesi for hypoactive sexual desire disorder, giving it a regulatory precedent absent from most other peptides in this category.
Kisspeptin
+
A hypothalamic neuropeptide encoded by the KISS1 gene serving as the principal upstream regulator of GnRH pulsatility and HPG axis activity. Its role as a master regulator of reproductive hormone production makes it relevant across a broad range of sexual health, fertility, and hormonal optimization contexts. Research into exogenous Kisspeptin administration for modulation of LH pulsatility and testosterone production in hypogonadal presentations is active.
Melanotan II
+
A synthetic analogue of alpha-MSH with potent non-selective melanocortin receptor agonist activity, producing tanning (MC1R), libido enhancement (MC3R/MC4R), and appetite suppression effects. Its central sexual arousal effects are among the most pronounced of any compound in the melanocortin class. Administration occurs under strict medical supervision given the compound's broad receptor activity profile.
Immune Modulation
Thymosin Alpha-1
+
A 28-amino acid thymic peptide with extensive clinical evidence supporting its immunomodulatory role — enhancing T-cell maturation, natural killer cell cytotoxicity, dendritic cell function, and innate immune surveillance. Approved for clinical use in multiple countries for hepatitis B, hepatitis C, and as an immune adjuvant in oncology and infectious disease contexts. Deployed within the group's immune restoration, longevity, and antiviral protocol frameworks. Reclassified from FDA Category 2 effective April 2026.
Thymosin Beta-4 (Systemic Immune Applications)
+
Beyond tissue repair applications, Thymosin Beta-4 exerts systemic immunomodulatory effects including downregulation of inflammatory cytokine production, modulation of macrophage and T-regulatory cell activity, and attenuation of autoimmune inflammatory cascades. These properties make it relevant in clinical contexts characterised by systemic inflammatory dysregulation, autoimmune conditions, and chronic post-infectious inflammatory states.
Science & Research

Grounded in Evidence.
Driven by Innovation.

Every protocol within the Suncoast Health Group portfolio is developed against a rigorous framework of peer-reviewed research, proprietary clinical data, and the group's established scientific governance standards. The group does not deploy emerging modalities without clinical grounding — it translates validated science into accessible, structured clinical practice through its affiliated network.

01
Proprietary Patent Portfolio
The group's therapeutic protocols are backed by intellectual property developed through sustained research and clinical refinement. Patent protection ensures protocol consistency, quality control, and accountability across all entities operating within the Suncoast Health Group network.
02
Evidence-Based Protocol Development
Each modality within the portfolio is evaluated against the published literature prior to deployment. A dedicated scientific advisory function continuously reviews emerging research to ensure all protocols reflect the current state of evidence and that validated advances are integrated in a timely manner.
03
Multi-Jurisdictional Clinical Governance
Affiliated clinical entities operate under the regulatory oversight of licensed medical boards across each jurisdiction — the United States, the Bahamas, and the Cayman Islands. All protocols are deployed by credentialed clinicians within the applicable regulatory and professional governance frameworks of each operating territory.
04
Outcomes Monitoring & Continuous Improvement
Structured clinical outcomes data is collected and analysed across the affiliated network to monitor protocol efficacy, identify refinement opportunities, and contribute to the growing real-world evidence base in regenerative medicine, longevity science, and peptide therapeutics.
34+
Protocol Modalities
5
Therapeutic Disciplines
3
Territories
1
Standard of Science
Core Scientific Modalities
Mesenchymal Stem CellsExosome Biology PRP / PRF TherapyPeptide Science Mitochondrial MedicineSenolytic Research mTOR BiologyTelomere Science NAD+ MetabolismShockwave Therapy PhotobiomodulationHormonal Optimization NutrigenomicsOzone Therapy Hyperbaric MedicineNeural Prolotherapy Wharton's Jelly MSCBMAC Therapy GH SecretagoguesMelanocortin Science GLP-1 AgonistsNeuropeptides
Enquiries

Connect With
the Group

For partnership enquiries, protocol licensing, investment discussions, media requests, or general correspondence, the Suncoast Health Group team welcomes your contact.

Group Headquarters
United States
Affiliated Clinical Network
United States  ·  Nassau, Bahamas
Grand Cayman, Cayman Islands
General Correspondence
info@scoastgh.com
Email Us Directly
info@scoastgh.com

We respond to all enquiries within two business days.

Send an Enquiry

Medical Disclaimer: The information published on this site is intended for educational and portfolio documentation purposes only. It does not constitute medical advice, clinical guidance, or a solicitation for treatment. All therapeutic protocols within the Suncoast Health Group portfolio are administered exclusively by licensed medical professionals within applicable regulatory frameworks.